RU2004116311A - Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции - Google Patents
Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции Download PDFInfo
- Publication number
- RU2004116311A RU2004116311A RU2004116311/04A RU2004116311A RU2004116311A RU 2004116311 A RU2004116311 A RU 2004116311A RU 2004116311/04 A RU2004116311/04 A RU 2004116311/04A RU 2004116311 A RU2004116311 A RU 2004116311A RU 2004116311 A RU2004116311 A RU 2004116311A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- ray diffraction
- diffraction pattern
- addiction
- measured
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 150000003890 succinate salts Chemical class 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 238000002441 X-ray diffraction Methods 0.000 claims 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 4
- 229910052802 copper Inorganic materials 0.000 claims 4
- 239000010949 copper Substances 0.000 claims 4
- 206010012335 Dependence Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020651 Hyperkinesia Diseases 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000003443 Unconsciousness Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000019505 tobacco product Nutrition 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Сукцинатная соль 5,8,14-триазатетрацикло-[10.3.1.02,11.04,9]-гексадека-2(11),3,5,7,9-пентаена.
2. Соединение по п.1, где соль является безводной.
3. Соединение по п.2, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, наличием пиков на рентгеновской дифрактограмме, как измерено с медным излучателем, при 2θ примерно 13,3 и 17,2.
4. Соединение по п.2, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, следующими главными пиками на рентгеновской дифрактограмме, выраженными в терминах 2θ и D-интервалов, как измерено с медным излучателем:
5. Соединение по п.2, отличающееся остановкой перехода плавление/разложение при примерно 198оС.
6. Фармацевтическая композиция, включающая соединение по п.2 и фармацевтически приемлемый носитель.
7. Соединение по п.1, где соль представляет собой гидрат.
8. Соединение по п.7, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, наличием пиков на рентгеновской дифрактограмме, как измерено с медным излучателем, при 2θ примерно 13,0, 16,5 и 19,0.
9. Соединение по п.7, имеющее рентгеновскую дифрактограмму, характеризуемую, главным образом, следующими главными пиками на рентгеновской дифрактограмме, выраженными в терминах 2θ и D-интервалов, как измерено с медным излучателем:
10. Способ лечения воспалительных заболеваний кишечника (включая, но не ограничиваясь этим, язвенный колит, гангренозную пиодермию и болезнь Крона), синдрома раздраженной толстой кишки, спастической дистонии, хронических болей, острых болей, нетропической спру (болезнью глютеновой недостаточности), воспаления брюшины, сужения сосудов, беспокойства, панического состояния, депрессии, биполярного расстройства, аутизма, расстройств сна, нарушения суточного ритма организма при перелете через несколько часовых поясов, бокового амиотрофического склероза (БАС), дисфункции познавательной способности, гипертонии, булимии, анорексии, тучности, сердечной аритмии, повышенной кислотности желудка, язвенных болезней, феохромоцитомы, прогрессивной надмышечной атрофии, зависимостей от химических веществ и пристрастия к ним (например, зависимости от или пристрастия к никотину (и/или табачным продуктам), алкоголю, бензодиазепинам, барбитуратам, опиоидам или кокаину), головной боли, мигрени, удара, травматического поражения мозга (ТПМ), обсессивно-компульсивного расстройства (ОКР), психоза, хореи Хантингтона, поздней дискинезии, гиперкинезии, дислексии, шизофрении, мультиинфарктного слабоумия, возрастного ухудшения познавательной способности, эпилепсии, включая эпилепсию кратковременной потери сознания, старческого слабоумия альцгеймеровского типа (болезнь Альцгеймера, БА), болезни Паркинсона (БП), расстройства дефицита внимания - гиперактивности (ADHD), и синдрома Туррета, включающий введение нуждающемуся в лечении субъекту терапевтически эффективного количества соединения по п.1.
11. Способ лечения никотиновой зависимости, пристрастия к никотину и синдрома абстиненции в отношении никотина у млекопитающих, включающий введение нуждающемуся в этом субъекту соединения по п.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33424501P | 2001-11-29 | 2001-11-29 | |
| US60/334,245 | 2001-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004116311A true RU2004116311A (ru) | 2005-03-27 |
Family
ID=23306297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116311/04A RU2004116311A (ru) | 2001-11-29 | 2002-10-21 | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6794388B2 (ru) |
| EP (1) | EP1461040B1 (ru) |
| JP (1) | JP4196829B2 (ru) |
| KR (1) | KR20040066140A (ru) |
| CN (1) | CN1589148A (ru) |
| AR (1) | AR037677A1 (ru) |
| AT (1) | ATE320256T1 (ru) |
| AU (1) | AU2002341327A1 (ru) |
| BR (1) | BR0214559A (ru) |
| CA (1) | CA2468705A1 (ru) |
| DE (1) | DE60209929T2 (ru) |
| DO (1) | DOP2002000512A (ru) |
| ES (1) | ES2258652T3 (ru) |
| GT (1) | GT200200236A (ru) |
| HN (1) | HN2002000332A (ru) |
| IL (1) | IL161326A0 (ru) |
| MX (1) | MXPA04003192A (ru) |
| PA (1) | PA8559401A1 (ru) |
| PE (1) | PE20030738A1 (ru) |
| PL (1) | PL374325A1 (ru) |
| RU (1) | RU2004116311A (ru) |
| SV (1) | SV2004001413A (ru) |
| TW (1) | TW200300345A (ru) |
| UY (1) | UY27548A1 (ru) |
| WO (1) | WO2003045394A1 (ru) |
| ZA (1) | ZA200402720B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2527970C2 (ru) * | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1044189T4 (en) * | 1997-12-31 | 2015-03-30 | Pfizer Prod Inc | Aryl-fused fused azapolycyclic connections |
| US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| JP2006528237A (ja) * | 2003-05-20 | 2006-12-14 | ファイザー・プロダクツ・インク | バレニクリンの医薬組成物 |
| CA2543201C (en) * | 2003-10-27 | 2010-12-21 | Merck & Co., Inc. | ((ir, 3s)-3-isopropyl-3-{ [3-(trifluoromethyl)-7, 8-dihydro-1, 6-naphthyridin-6 (5h)-yl] carbonyl} cyclopentyl) [(3s, 4s)-3-methoxytetrahydro-2h-pyran-4-yl] amine succinate salt, composition thereof, and its use in the treatment of inflammatory diseases |
| HRP20070078A2 (hr) | 2004-07-27 | 2007-05-31 | Gilead Sciences | Fosfonatni analozi spojeva koji inhibiraju hiv |
| US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| KR100734147B1 (ko) * | 2005-07-29 | 2007-07-02 | 주식회사 엘지데이콤 | 호 알림 지연을 통한 멀티미디어 통화연결음 서비스 시스템및 방법 |
| PT2020996E (pt) * | 2006-05-16 | 2012-02-20 | Gilead Sciences Inc | Método e composições para tratar neoplasias malignas hematológicas |
| AU2007319951A1 (en) * | 2006-11-09 | 2008-05-22 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
| CN101611029B (zh) * | 2006-12-21 | 2014-09-10 | 辉瑞产品公司 | 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐 |
| US8440825B2 (en) | 2008-03-06 | 2013-05-14 | Medichem S.A. | Fumaric acid salt of varenicline |
| WO2009143347A2 (en) | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
| PT2307435E (pt) * | 2008-07-08 | 2012-09-19 | Gilead Sciences Inc | Sais de compostos inibidores de vih |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| CA2801842A1 (en) | 2009-06-10 | 2010-12-16 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
| WO2010151524A1 (en) | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
| WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
| EP2837632B1 (en) | 2012-04-13 | 2016-05-18 | Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. | Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases |
| BR112017008097B1 (pt) | 2014-10-20 | 2023-03-28 | Oyster Point Pharma, Inc | Método para tratar condições oculares |
| DK3439661T3 (da) | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
| WO2019027920A1 (en) | 2017-08-01 | 2019-02-07 | Gilead Sciences, Inc. | CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1044189T4 (en) * | 1997-12-31 | 2015-03-30 | Pfizer Prod Inc | Aryl-fused fused azapolycyclic connections |
| JP2003509341A (ja) | 1999-08-27 | 2003-03-11 | イネックス ファーマスーティカルズ コーポレイション | サイトカインの分泌刺激および免疫応答の誘導組成物 |
| TWI236930B (en) * | 2000-05-26 | 2005-08-01 | Pfizer Prod Inc | Reactive crystallization method to improve particle size |
-
2002
- 2002-10-21 DE DE60209929T patent/DE60209929T2/de not_active Expired - Fee Related
- 2002-10-21 CA CA002468705A patent/CA2468705A1/en not_active Abandoned
- 2002-10-21 KR KR10-2004-7008116A patent/KR20040066140A/ko not_active Ceased
- 2002-10-21 MX MXPA04003192A patent/MXPA04003192A/es active IP Right Grant
- 2002-10-21 EP EP02775143A patent/EP1461040B1/en not_active Expired - Lifetime
- 2002-10-21 PL PL02374325A patent/PL374325A1/xx not_active Application Discontinuation
- 2002-10-21 IL IL16132602A patent/IL161326A0/xx unknown
- 2002-10-21 CN CNA028229304A patent/CN1589148A/zh active Pending
- 2002-10-21 AU AU2002341327A patent/AU2002341327A1/en not_active Abandoned
- 2002-10-21 WO PCT/IB2002/004380 patent/WO2003045394A1/en not_active Ceased
- 2002-10-21 JP JP2003546896A patent/JP4196829B2/ja not_active Expired - Fee Related
- 2002-10-21 BR BRPI0214559-6A patent/BR0214559A/pt not_active IP Right Cessation
- 2002-10-21 AT AT02775143T patent/ATE320256T1/de not_active IP Right Cessation
- 2002-10-21 RU RU2004116311/04A patent/RU2004116311A/ru not_active Application Discontinuation
- 2002-10-21 ES ES02775143T patent/ES2258652T3/es not_active Expired - Lifetime
- 2002-11-13 DO DO2002000512A patent/DOP2002000512A/es unknown
- 2002-11-22 GT GT200200236A patent/GT200200236A/es unknown
- 2002-11-25 TW TW091134190A patent/TW200300345A/zh unknown
- 2002-11-25 PE PE2002001130A patent/PE20030738A1/es not_active Application Discontinuation
- 2002-11-26 UY UY27548A patent/UY27548A1/es not_active Application Discontinuation
- 2002-11-27 US US10/305,845 patent/US6794388B2/en not_active Expired - Fee Related
- 2002-11-27 HN HN2002000332A patent/HN2002000332A/es unknown
- 2002-11-27 AR ARP020104558A patent/AR037677A1/es unknown
- 2002-11-28 SV SV2002001413A patent/SV2004001413A/es not_active Application Discontinuation
- 2002-11-29 PA PA20028559401A patent/PA8559401A1/es unknown
-
2004
- 2004-04-07 ZA ZA200402720A patent/ZA200402720B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2527970C2 (ru) * | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE320256T1 (de) | 2006-04-15 |
| HN2002000332A (es) | 2003-12-11 |
| US6794388B2 (en) | 2004-09-21 |
| PL374325A1 (en) | 2005-10-17 |
| JP4196829B2 (ja) | 2008-12-17 |
| DOP2002000512A (es) | 2003-05-31 |
| BR0214559A (pt) | 2007-03-13 |
| SV2004001413A (es) | 2004-05-07 |
| CN1589148A (zh) | 2005-03-02 |
| WO2003045394A1 (en) | 2003-06-05 |
| AU2002341327A1 (en) | 2003-06-10 |
| PA8559401A1 (es) | 2004-02-07 |
| US20030149044A1 (en) | 2003-08-07 |
| ES2258652T3 (es) | 2006-09-01 |
| EP1461040B1 (en) | 2006-03-15 |
| DE60209929T2 (de) | 2006-11-16 |
| GT200200236A (es) | 2003-06-25 |
| CA2468705A1 (en) | 2003-06-05 |
| JP2005513032A (ja) | 2005-05-12 |
| ZA200402720B (en) | 2005-05-18 |
| AR037677A1 (es) | 2004-12-01 |
| PE20030738A1 (es) | 2003-08-28 |
| DE60209929D1 (de) | 2006-05-11 |
| UY27548A1 (es) | 2003-06-30 |
| TW200300345A (en) | 2003-06-01 |
| MXPA04003192A (es) | 2004-07-27 |
| EP1461040A1 (en) | 2004-09-29 |
| IL161326A0 (en) | 2004-09-27 |
| KR20040066140A (ko) | 2004-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004116311A (ru) | Сукцинатные соли 5,8,14-триазатетрацикло [10.3.1.02,11(04,9]гексадека- 2(11),3,5,7,9-пентаена и их фармацевтические композиции | |
| DE60318860T2 (de) | Chinucledin - derivate und deren verwendung | |
| EP1551835B1 (en) | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | |
| EP1881979B1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2004533446A5 (ru) | ||
| EP1562945B1 (en) | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof | |
| US7524838B2 (en) | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | |
| JP7323179B2 (ja) | 排出ポンプ阻害剤としてのインドール誘導体 | |
| NZ528210A (en) | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
| EP1713487B1 (en) | Diazabicyclic aryl derivatives as cholinergic receptor modulators | |
| US7750011B2 (en) | Diazabicyclic aryl derivatives and their medical use | |
| JP2643274B2 (ja) | イミダゾ〔１，２−ａ〕ピリジン誘導体 | |
| EP1390366B1 (en) | The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene | |
| WO2006087306A2 (en) | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors | |
| EP1713809B1 (en) | Dimeric azacyclic compounds and their use | |
| WO2003005998A3 (en) | A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function | |
| JP4530597B2 (ja) | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 | |
| JPWO2001009131A1 (ja) | アザインドリジノン誘導体及びそれを有効成分とする脳機能改善剤 | |
| US7612074B2 (en) | Diazabicyclic aryl derivatives as cholinergy ligands | |
| JPH11512444A (ja) | 新規置換アザ環式またはアザ二環式化合物 | |
| JP2719063B2 (ja) | 置換３−アミノキヌクリジンｐ物質拮抗剤 | |
| CN101087610A (zh) | 芳基哌嗪衍生物及其作为5－ht1a受体配体的用途 | |
| EP1656375A1 (en) | Novel quinuclidine derivatives and their pharmaceutical use | |
| HK1080860B (en) | Novel quinuclidine derivatives and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050526 |